Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
EDAP's Cash to Debt is ranked higher than
93% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. EDAP: No Debt )
EDAP' s 10-Year Cash to Debt Range
Min: 0.37   Max: No Debt
Current: No Debt

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -11.44
EDAP's Operating margin (%) is ranked higher than
55% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 6.50 vs. EDAP: -11.44 )
EDAP' s 10-Year Operating margin (%) Range
Min: -43.96   Max: -2.5
Current: -11.44

-43.96
-2.5
Net-margin (%) -20.85
EDAP's Net-margin (%) is ranked higher than
54% of the 371 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. EDAP: -20.85 )
EDAP' s 10-Year Net-margin (%) Range
Min: -53.64   Max: 42.97
Current: -20.85

-53.64
42.97
ROE (%) -54.08
EDAP's ROE (%) is ranked lower than
51% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 5.93 vs. EDAP: -54.08 )
EDAP' s 10-Year ROE (%) Range
Min: -142.89   Max: 33.77
Current: -54.08

-142.89
33.77
ROA (%) -18.68
EDAP's ROA (%) is ranked higher than
55% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. EDAP: -18.68 )
EDAP' s 10-Year ROA (%) Range
Min: -35.39   Max: 23.29
Current: -18.68

-35.39
23.29
ROC (Joel Greenblatt) (%) -39.40
EDAP's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 13.69 vs. EDAP: -39.40 )
EDAP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -95.07   Max: -4.39
Current: -39.4

-95.07
-4.39
Revenue Growth (%) -13.70
EDAP's Revenue Growth (%) is ranked higher than
50% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. EDAP: -13.70 )
EDAP' s 10-Year Revenue Growth (%) Range
Min: -14.3   Max: 3.5
Current: -13.7

-14.3
3.5
EBITDA Growth (%) -40.10
EDAP's EBITDA Growth (%) is ranked higher than
53% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. EDAP: -40.10 )
EDAP' s 10-Year EBITDA Growth (%) Range
Min: -70.7   Max: 155.4
Current: -40.1

-70.7
155.4
EPS Growth (%) -37.40
EDAP's EPS Growth (%) is ranked higher than
52% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. EDAP: -37.40 )
EDAP' s 10-Year EPS Growth (%) Range
Min: -37.4   Max: 261.7
Current: -37.4

-37.4
261.7
» EDAP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

EDAP Guru Trades in Q2 2013

Robert Bruce 1,565,494 sh (unchged)
» More
Q3 2013

EDAP Guru Trades in Q3 2013

Robert Bruce 1,565,494 sh (unchged)
» More
Q4 2013

EDAP Guru Trades in Q4 2013

Robert Bruce 1,565,494 sh (unchged)
» More
Q1 2014

EDAP Guru Trades in Q1 2014

Robert Bruce 1,565,494 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with EDAP



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 3.10
EDAP's P/S is ranked higher than
68% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. EDAP: 3.10 )
EDAP' s 10-Year P/S Range
Min: 0.52   Max: 6.68
Current: 3.1

0.52
6.68
EV-to-EBIT -86.70
EDAP's EV-to-EBIT is ranked higher than
58% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 44.62 vs. EDAP: -86.70 )
EDAP' s 10-Year EV-to-EBIT Range
Min: 32.4   Max: 36.5
Current: -86.7

32.4
36.5

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 2.10
EDAP's Price/Median PS Value is ranked higher than
54% of the 411 Companies
in the Global Medical Devices industry.

( Industry Median: 1.18 vs. EDAP: 2.10 )
EDAP' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 4.61
Current: 2.1

0.26
4.61
Earnings Yield (Greenblatt) 74.40
EDAP's Earnings Yield (Greenblatt) is ranked higher than
99% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. EDAP: 74.40 )
EDAP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.7   Max: 74.4
Current: 74.4

2.7
74.4
Forward Rate of Return (Yacktman) -6.41
EDAP's Forward Rate of Return (Yacktman) is ranked higher than
63% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. EDAP: -6.41 )
EDAP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.4   Max: -17.5
Current: -6.41

-19.4
-17.5

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:EDA.Germany
EDAP TMS SA was incorporated on December 3, 1979 as a Societe Anonyme organized under the laws of the Republic of France for 60 years from the date of incorporation. It is a holding Company and is responsible for providing common services to its subsidiaries, including preparation and consolidation of the financial statements for the group, complying with the requirements of various regulatory agencies and maintaining the listing of its publicly held securities. Its activity is organized in two divisions: HIFU and UDS (including lithotripsy activities). Through these two divisions, the Company develops, produces and markets minimally invasive medical devices, mainly for urological diseases. It believes that the creation of these two divisions has allowed expanding its market share by optimizing worldwide distribution capabilities, all of which is coordinated through its subsidiaries. It's HIFU and UDS divisions operate in Europe, the Americas, Asia and the rest of the world. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. Its HIFU business is quite seasonal and generally linked to lengthy hospital decision and investment processes. In addition to developing, manufacturing and marketing HIFU devices, the HIFU division also generates revenues from leasing equipment, as well as from the sale of disposables, spare parts and maintenance services. Currently, the only commercial product of the Company utilizing HIFU technology is the Ablatherm, an ultrasound guided HIFU device for the treatment of organ-confined prostate cancer. As of December 31, 2012, the HIFU division's patent portfolio contained 36 patents consisting of 17 in the United States, 17 in the European Union and Japan and 2 in Israel and the rest of the world. They belong to 18 groups of patents covering key technologies related to therapeutic ultrasound principles, systems and associated software. As of December 31, 2012, its clinical Ablatherm-HIFU result has been published in 70 renowned peer-reviewed journals. The UDS division's main business is producing and marketing devices, known as lithotripters, for the treatment of urinary tract stones by means of ESWL technology. In addition to its manufacturing and selling of lithotripters, the UDS division also generates revenues from the leasing of lithotripters, as well as from the sale of disposables, spare parts and maintenance services. The UDS division offers the Sonolith i-move to small and mid-size hospitals, while the Sonolith i-sys is offered to large hospitals that can afford a fully dedicated and integrated lithotripter. Ablatherm-HIFU device competes with all current treatments for localized tumors, which include surgery, brachytherapy, radiotherapy, cryotherapy and hormonotherapy.
» More Articles for NAS:EDAP

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
EDAP Completes FDA Inspection of Manufacturing Site Jun 27 2014
EDAP Completes FDA Inspection of Manufacturing Site Jun 27 2014
Coverage initiated on EDAP TMS SA by H.C. Wainwright Jun 16 2014
EDAP Closes $9.3 Million Registered Direct Offering Jun 03 2014
EDAP to Raise $9.3 Million in Registered Direct Offering May 28 2014
EDAP details additional milestones in Ablatherm-HIFU PMA process May 27 2014
EDAP Outlines Key Events Scheduled in the Ablatherm-HIFU PMA Process May 27 2014
EDAP's Ablatherm-HIFU FDA Panel Meeting Confirmed for July 30, 2014 May 22 2014
EDAP Highlights Its HIFU and Lithotripsy Technologies at 109th Annual AUA Meeting May 16 2014
EDAP TMS' (EDAP) CEO Marc Oczachowski on Q1 2014 Results - Earnings Call Transcript May 15 2014
EDAP TMS S.A. (EDAP) Q1 2014 Results - Earnings Call Webcast May 15 2014
EDAP TMS reports Q1 EPS 5c, one estimate (4c) May 15 2014
EDAP Reports First Quarter 2014 Results May 15 2014
EDAP Announces First Focal One(R) HIFU Treatments Performed in Germany May 06 2014
EDAP Schedules Webcast and Conference Call for First Quarter 2014 Results May 01 2014
EDAP Announces European Association of Urology Recommends HIFU for Treatment of Localized Prostate... Apr 24 2014
EDAP Announces European Association of Urology Recommends HIFU for Treatment of Localized Prostate... Apr 24 2014
EDAP TMS SA Financials Apr 09 2014
EDAP's CEO Discusses Q4 2013 Results - Earnings Call Transcript Apr 03 2014
EDAP TMS S.A. Discusses Q4 2013 Results (Webcast) Apr 03 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide